# US 2010/0168174 A1 · Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168174 A1
- Document ID: US20100168174A1
- Status: Published application
- Kind: A1
- Application number: 12/663,550
- Filed: 2008-07-11
- Published: 2010-07-01
- Earliest claimed: 2007-07-13
- Assignees: Eisai R&D Management Co., Ltd.
- Inventors: Takahisa Hanada
- Web page: https://patentgrep.com/patent/US20100168174A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine (donepezil).

## Claims

### Claim 1

A pharmaceutical composition comprising:
(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof;
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof; an anti-neuropathic pain agent; or a mixture or combination thereof; and
(C) one or more pharmaceutically acceptable carriers.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the AMPA receptor antagonist, pharmaceutically acceptable salt thereof, hydrate thereof, or hydrate of the pharmaceutically acceptable salt thereof is a compound of Formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof; wherein the compound of Formula (III) is:
wherein X1, X2 and X3 are each independently a single bond, an optionally substituted C1-6 alkylene, an optionally substituted C2-6 alkenylene, an optionally substituted C2-6 alkynylene, —O—, —S—, —CO—, —SO—, —SO2—, —N(R6)—, —N(R7)—CO—, —CO—N(R8)—, —N(R9)—CH2—, —CH2—N(R10)—, —CH2—CO—, —CO—CH2—, —N(R11)—S(O)m—, —S(O)n—N(R12)—, —CH2—S(O)p—, —S(O)q—CH2—, —CH2—O—, —O—CH2—, —N(R13)—CO—N(R14)— or —N(R15)—CS—N(R16); R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen, C1-6 alkyl, or C1-6 alkoxy; m, n, p and q are each independently an integer of 0, 1 or 2; A1, A2 and A3 are each independently an optionally substituted C3-8 cycloalkyl, an optionally substituted C3-8 cycloalkenyl, an optionally substituted 5- to 14-membered non-aromatic heterocyclic ring, an optionally substituted C6-14 aromatic hydrocarbocyclic ring, or an optionally substituted 5 to 14-membered aromatic heterocyclic ring; and R17 and R18 are each independently hydrogen, halogen, or C1-6 alkyl.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof is 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cholinesterase inhibitor or a pharmaceutically acceptable salt thereof is at least one compound selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof; rivastigmine or a pharmaceutically acceptable salt thereof; and galanthamine or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anti-neuropathic pain agent is at least one compound selected from the group consisting of gabapentin, pregabalin, duloxetine, mexiletine, lidocaine, amytriptyline, imipramine, clomipramine, desipramine, nortriptyline, maprotiline, paroxetine, fluoxetine, citalopram, venlafaxine, bupropion, carbamazepine, oxcabazepine, phenyloin, lamotrigine, valproate, topiramate, levetiracetam, tiagabine, lacosamide, brivaracetam tramadol, oxycodone, morphine, fentanyl, methadone, dextromethorphan, memantine, ketamine, riluzole, dronabinol, THC, capsaicin, clonidine, baclofen, tizanidine, AVP-923, desvenlafaxine succinate, bicifadine, OPC-14523, NGX4010, ralfinamide, XP-13512, KDS-2000, CNS-5161, V-3381, GW-493838, GW-353162, CCI-1008, SS-RBX, cannabidiol, RGH-896, SAB-378, TV-1901, ABT-894, TAK-583 and AGN-203818.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is used for treating neuropathic pain.

### Claim 7

A combination comprising:
(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof; and
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof; an anti-neuropathic pain agent; or a mixture or combination thereof.

### Claim 8 (depends on 7)

The combination of claim 7, wherein the AMPA receptor antagonist, pharmaceutically acceptable salt thereof, hydrate thereof, or hydrate of the pharmaceutically acceptable salt thereof is a compound of Formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof; wherein the compound of Formula (III) is:
wherein X1, X2 and X3 are each independently a single bond, an optionally substituted C1-6 alkylene, an optionally substituted C2-6 alkenylene, an optionally substituted C2-6 alkynylene, —O—, —S—, —CO—, —SO—, —SO2—, —N(R6)—, —N(R7)—CO—, —CO—N(R8)—, —N(R9)—CH2—, —CH2—N(R10)—, —CH2—CO—, —CO—CH2—, —N(R11)—S(O)m—, —S(O)n—N(R12)—, —CH2—S(O)p—, —S(O)q—CH2—, —CH2—O—, —O—CH2—, —N(R13)—CO—N(R14)— or —N(R15)—CS—N(R16); R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen, C1-6 alkyl, or C1-6 alkoxy; m, n, p and q are each independently an integer of 0, 1 or 2; A1, A2 and A3 are each independently an optionally substituted C3-8 cycloalkyl, an optionally substituted C3-8 cycloalkenyl, an optionally substituted 5- to 14-membered non-aromatic heterocyclic ring, an optionally substituted C6-14 aromatic hydrocarbocyclic ring, or an optionally substituted 5 to 14-membered aromatic heterocyclic ring; and R17 and R18 are each independently hydrogen, halogen, or C1-6 alkyl.

### Claim 9 (depends on 7)

The combination of claim 7, wherein the AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof is 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 7)

The combination of claim 7, wherein the cholinesterase inhibitor or a pharmaceutically acceptable salt thereof is at least one compound selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof; rivastigmine or a pharmaceutically acceptable salt thereof; and galanthamine or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 7)

The combination of claim 7, wherein the anti-neuropathic pain agent is at least one compound selected from the group consisting of gabapentin, pregabalin, duloxetine, mexiletine, lidocaine, amytriptyline, imipramine, clomipramine, desipramine, nortriptyline, maprotiline, paroxetine, fluoxetine, citalopram, venlafaxine, bupropion, carbamazepine, oxcabazepine, phenyloin, lamotrigine, valproate, topiramate, levetiracetam, tiagabine, lacosamide, brivaracetam tramadol, oxycodone, morphine, fentanyl, methadone, dextromethorphan, memantine, ketamine, riluzole, dronabinol, THC, capsaicin, clonidine, baclofen, tizanidine, AVP-923, desvenlafaxine succinate, bicifadine, OPC-14523, NGX4010, ralfinamide, XP-13512, KDS-2000, CNS-5161, V-3381, GW-493838, GW-353162, CCI-1008, SS-RBX, cannabidiol, RGH-896, SAB-378, TV-1901, ABT-894, TAK-583 and AGN-203818.

### Claim 12 (depends on 7)

The combination of claim 7, wherein (A) and (B) are administered separately to a patient or are administered to a patient in the form of a pharmaceutical composition.

### Claim 13 (depends on 7)

The combination of claim 7, wherein the combination is used for treating neuropathic pain.

### Claim 14

Use of compounds (A) and (B) for producing a pharmaceutical composition in the treatment of neuropathic pain, wherein (A) and (B) are:
(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof; and
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof; an anti-neuropathic pain agent; or a mixture or combination thereof.

### Claim 15 (depends on 14)

The use of claim 14, wherein the AMPA receptor antagonist, pharmaceutically acceptable salt thereof, hydrate thereof, or hydrate of the pharmaceutically acceptable salt thereof is a compound of Formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof, wherein the compound of Formula (III) is:
wherein X1, X2 and X3 are each independently a single bond, an optionally substituted C1-6 alkylene, an optionally substituted C2-6 alkenylene, an optionally substituted C2-6 alkynylene, —O—, —S—, —CO—, —SO—, —SO2—, —N(R6)—, —N(R7)—CO—, —CO—N(R8)—, —N(R9)—CH2—, —CH2—N(R10)—, —CH2—CO—, —CO—CH2—, —N(R11)—S(O)m—, —S(O)N—N(R12)—, —CH2—S(O)p—, —S(O)q—CH2—, —CH2—O—, —O—CH2—, —N(R13)—CO—N(R14)— or —N(R15)—CS—N(R16); R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen, C1-6 alkyl, or C1-6 alkoxy; m, n, p and q are each independently an integer of 0, 1 or 2; A1, A2 and A3 are each independently an optionally substituted C3-8 cycloalkyl, an optionally substituted C3-8 cycloalkenyl, an optionally substituted 5- to 14-membered non-aromatic heterocyclic ring, an optionally substituted C6-14 aromatic hydrocarbocyclic ring, or an optionally substituted 5 to 14-membered aromatic heterocyclic ring; and R17 and R18 are each independently hydrogen, halogen, or C1-6 alkyl.

### Claim 16 (depends on 14)

The use of claim 14, wherein the AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof is 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 14)

The use of claim 14, wherein the cholinesterase inhibitor or a pharmaceutically acceptable salt thereof is at least one compound selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof; rivastigmine or a pharmaceutically acceptable salt thereof; and galanthamine or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 14)

The use of claim 14, wherein the anti-neuropathic pain agent is at least one compound selected from the group consisting of gabapentin, pregabalin, duloxetine, mexiletine, lidocaine, amytriptyline, imipramine, clomipramine, desipramine, nortriptyline, maprotiline, paroxetine, fluoxetine, citalopram, venlafaxine, bupropion, carbamazepine, oxcabazepine, phenyloin, lamotrigine, valproate, topiramate, levetiracetam, tiagabine, lacosamide, brivaracetam tramadol, oxycodone, morphine, fentanyl, methadone, dextromethorphan, memantine, ketamine, riluzole, dronabinol, THC, capsaicin, clonidine, baclofen, tizanidine, AVP-923, desvenlafaxine succinate, bicifadine, OPC-14523, NGX4010, ralfinamide, XP-13512, KDS-2000, CNS-5161, V-3381, GW-493838, GW-353162, CCI-1008, SS-RBX, cannabidiol, RGH-896, SAB-378, TV-1901, ABT-894, TAK-583 and AGN-203818.

### Claim 19 (depends on 14)

The use of claim 14, wherein (A) and (B) are administered separately to a patient or are administered to a patient in the form of a pharmaceutical composition.

### Claim 20

Compounds (A) and (B) for use in the treatment of neuropathic pain, wherein (A) and (B) are:
(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof, and
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof; an anti-neuropathic pain agent; or a mixture or combination thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A kit comprising the pharmaceutical composition of any one of claims 1 to 6 or the combination of any one of claims 7 to 13.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method for treating neuropathic pain comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 6 or a therapeutically effective amount of the combination of any one of claims 7 to 13.
